The liquid biopsy field has no shortage of grand promises—cancer caught early from a vial of blood, treatment decisions made in days instead of weeks. What it does have a shortage of, perhaps surprisingly, is easy ways to actually process that blood.
BIOCAPTIVA, a University of Edinburgh spin-out working on that unglamorous but crucial pre-analytical step, announced £1.58 million in fresh funding this week. The March 10 round was led by Archangels, the Scottish investment syndicate that's backed the company since its 2021 founding, with participation from Old College Capital, BBI, Scottish Enterprise, and a new backer, EverQuest Capital Partners.
Timing matters here. The funding arrives just as the company launches its first commercial product in the U.S.—magnetic bead kits designed to pull cell-free DNA directly from whole blood without the centrifugation or plasma separation steps that typically come first. The kits, branded msX-B, debuted quietly at the SLAS conference in Boston in early February and are now available through an early access program for research labs.
"We're not trying to run the assay," CEO Jeremy Wheeler might say if pressed to distill the pitch. "We're trying to make sure what goes into the assay is actually usable."
A Polymer That Sticks
At the core of BIOCAPTIVA's approach is a polymer coating—msX—that the company says can bind nucleic acids from messy biological fluids and keep captured DNA stable at room temperature. The technology can be layered onto various substrates; in this case, magnetic beads that labs already know how to work with. Two U.S. patents covering the method were issued in July 2024 and January 2025.
The pitch is straightforward: skip a step, improve yield, simplify logistics. Whether that translates to a defendable moat in a crowded molecular diagnostics market is another question entirely.
BIOCAPTIVA has raised roughly £4.68 million across three equity rounds since spinning out. The 2021 seed brought in over £1 million from Archangels and Scottish Enterprise. A £2.1 million extension followed in June 2022, adding Cancer Research Horizons and Old College Capital to the cap table. Now, with this latest tranche, the company is adding commercial heft alongside capital.
Hiring for Scale
On the same day as the funding news, BIOCAPTIVA named Alan Schafer as chief technology officer. Schafer comes from Inivata, a UK liquid biopsy company that NeoGenomics acquired for $415 million in 2021—a rare exit of that size in European diagnostics. His arrival suggests Wheeler and the board see a path beyond research-use kits toward something more scalable, though the company isn't saying much about timelines.
The scientific founders—Professors Tim Aitman and Mark Bradley from Edinburgh—remain involved as advisors, lending academic credibility even as the company pivots toward commercialization.
The Device That Wasn't (Yet)
Notably absent from this week's announcement: any mention of BioCaptis, an apheresis-adjacent device the company once positioned as a clinical centerpiece. Early materials suggested first-in-human studies were planned for 2022 or 2023. Those trials haven't materialized publicly, and the company's current focus appears firmly on the extraction kits. It's possible the device program is on hold, or it's possible BIOCAPTIVA is simply taking a staged approach—secure revenue with kits, validate the platform, then return to the higher-risk, higher-reward device play.
No one from the company was available to clarify.
Context: A Crowded, Growing Field
The liquid biopsy market continues to draw outsized attention relative to its current revenue base. Grand View Research pegs the global market at $13.60 billion in 2025, projecting growth to $32.57 billion by 2033. Those figures should be taken with the usual grain of salt—market sizing in nascent diagnostic categories tends toward optimism—but the directional trend is clear. Blood-based testing for cancer and other diseases is moving from research curiosity to clinical reality, and the infrastructure to support it is still being built.
BIOCAPTIVA is betting that infrastructure play—not the flashiest part of the value chain—could be lucrative if the technology delivers on its efficiency claims. The company is targeting precision medicine labs and diagnostics developers, particularly in oncology, where sample quality can make or break an assay.
Whether a polymer-coated bead can carve out a durable position in a field increasingly dominated by automation and vertical integration remains to be seen. But for now, BIOCAPTIVA has a product, a CTO with an exit on his résumé, and enough runway to find out if labs will pay for simpler workflows.
That's more than many spin-outs can say.
